Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

• Main Authors: Ghazaleh Khalili-Tanha, Meysam Moghbeli
• Format: Article
• Language: English
• Published: BMC 2021-08-01
• Series: Cellular & Molecular Biology Letters
• Subjects: Doxorubicin; Drug resistance; Cancer; Chemotherapy
• Online Access: https://doi.org/10.1186/s11658-021-00282-9

Abstract Resistance against conventional chemotherapeutic agents is one of the main reasons for tumor relapse and poor clinical outcomes in cancer patients. Various mechanisms are associated with drug resistance, including drug efflux, cell cycle, DNA repair and apoptosis. Doxorubicin (DOX) is a widely used first-line anti-cancer drug that functions as a DNA topoisomerase II inhibitor. However, DOX resistance has emerged as a large hurdle in efficient tumor therapy. Furthermore, despite its wide clinical application, DOX is a double-edged sword: it can damage normal tissues and affect the quality of patients’ lives during and after treatment. It is essential to clarify the molecular basis of DOX resistance to support the development of novel therapeutic modalities with fewer and/or lower-impact side effects in cancer patients. Long non-coding RNAs (lncRNAs) have critical roles in the drug resistance of various tumors. In this review, we summarize the state of knowledge on all the lncRNAs associated with DOX resistance. The majority are involved in promoting DOX resistance. This review paves the way to introducing an lncRNA panel marker for the prediction of the DOX response and clinical outcomes for cancer patients.